Medical Psilocybin Act

Continue on your trip...

Cybin Granted Two New Patents For DMT Program

New Study Shows Psilocybin More Cost-Effective Than Traditional Therapies

[bsa_pro_ad_space id=2]

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress, and cluster headaches.

With only days left in New York’s legislative session before June 4, this is a really important moment for visibility and public support as advocates work to move the bill through both chambers.

The biggest priority right now is getting as many New Yorkers as possible to speak up to their state assembly members and senators in support of the bill, and to spread awareness across platforms while momentum is building.

Here are some resources to make this easy to share:

HERE is a ready-to-use outreach template with everything New Yorkers need to contact key State legislators
HERE is the recent press release
HERE is the bill text

Medical Psilocybin Act

Cybin Granted Two New Patents For DMT Program

New Study Shows Psilocybin More Cost-Effective Than Traditional Therapies

Madison Roberts

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn't Fully Realized It Yet

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

Follow us on social